New Hope Against Oral Cancer: Thienopyrimidines Show Strong Selectivity in Targeting Tumor Cells

Oral cancer continues to be a major health challenge worldwide, with oral squamous cell carcinoma (OSCC) ranking among the most aggressive and difficult-to-treat cancers of the head and neck. A new study by Prof. Biliana Nikolova and her research team at the Bulgarian Academy of Sciences has introduced a promising direction in selective cancer therapy using thienopyrimidine-based compounds.

Title: Targeting oral squamous cell carcinoma with thienopyrimidines

🧬 Research Insight

The research explored seven novel 2-substituted 4-amino-thieno[2,3-d]pyrimidines—originally designed as DPP-4 inhibitors—for their cytotoxic and selective effects against oral cancer cells. Tests were performed on SCC-9 and HSC-3 cell lines, along with normal HaCaT keratinocytes to evaluate compound safety and specificity.

🌟 Major Findings

• Compound 6 stood out with the highest selectivity index (SI = 22.3 for SCC-9 and SI = 6.4 for HSC-3), showing strong anticancer potential.
• Compound 4 also displayed impressive selectivity (SI = 12.8), while compound 5 performed comparably to doxorubicin.
• Advanced biophysical analyses, including FACS, colony-forming, and cell migration assays, confirmed their ability to inhibit cancer cell growth and spread.
• The study highlights compound 6 as a lead candidate for further development as a selective oral cancer therapeutic with reduced side effects on normal cells.

👩‍🔬 About the Scientist

Prof. Biliana Nikolova is a distinguished biophysicist specializing in the impact of electric fields and nanomedicine applications in cancer therapy. At the Institute of Biophysics and Biomedical Engineering, she leads pioneering research that bridges biophysics, electrotherapy, and biomedical engineering. Her work continues to inspire new strategies in targeted cancer treatment and tissue regeneration.

🌍 Presented At

🧫 International Conference on Cancer Science and Research
📅 November 17–19, 2025 | Singapore & Online
🌐 https://cancer.miconferences.com/

---

#OralCancerResearch #CancerScience #Biophysics #Thienopyrimidines #CancerInnovation #CancerTherapy #BiomedicalResearch #OSCC #CancerWorldConf #Cancer2025 #OncologyUpdates #CancerConferenceSingapore

Breaking Barriers in Breast Cancer Therapy: How 2NF and Safingol Work Together to Stop Tumor Growth

A remarkable new study by Dr. Viviana C. Blank from the University of Buenos Aires, Argentina, shines light on a powerful drug combination that could change the way we treat breast cancer. Her research uncovers how two compounds — 2´nitroflavone (2NF) and safingol — work together to attack cancer cells through multiple molecular pathways.

Dr. Blank will be presenting her latest findings at the upcoming International Conference on Cancer Science and Research, happening November 17–19, 2025, in Singapore and Online.

🎯 Title: Synergistic antitumor effects of 2NF and safingol combination in breast cancer: Molecular mechanisms involving SPHK1, MAPKs, and ER stress

---

🔍 What Makes This Research Stand Out

The study focuses on disrupting the SPHK1/sphingosine-1-phosphate (S1P) signaling axis — a crucial mechanism that helps cancer cells survive and multiply. By combining 2NF, a flavonoid with known anticancer potential, and safingol, a sphingosine kinase inhibitor, Dr. Blank and her team observed remarkable synergistic antitumor effects in breast cancer models.

---

⚗️ Key Discoveries from the Study

·         🧬 Molecular Targeting: 2NF directly interacts with SPHK1 near the Ser225 site, preventing phosphorylation and blocking its translocation to the cell membrane.

·         💥 Enhanced Tumor Cell Death: The 2NF and safingol combination significantly reduces cancer cell proliferation and promotes apoptosis.

·         🔬 MAPK Activation: The dual treatment triggers key signaling pathways — p38, JNK, and ERK MAPKs — which play a central role in cell stress and death.

·         ⚙️ ER Stress Induction: The combination boosts endoplasmic reticulum (ER) stress responses, further contributing to tumor cell destruction.

·         🧪 Therapeutic Implication: Findings suggest a multi-targeted therapeutic approach could be more effective than single-drug treatments in breast cancer management.

---

👩‍🔬 About Dr. Viviana C. Blank

Dr. Blank is a biochemist and senior researcher at the University of Buenos Aires and a member of CONICET. She holds a Ph.D. in Biological Chemistry and has dedicated her career to exploring flavonoids and synthetic molecules with anticancer activity.
Her passion lies in uncovering molecular mechanisms of tumor inhibition and developing potential therapeutic strategies that can improve patient outcomes.

---

🧭 Conference Information

📅 Dates: November 17–19, 2025
📍 Venue: Singapore & Online (Hybrid Event)
🎓 Event: International Conference on Cancer Science and Research
🌐 Website: https://cancer.miconferences.com/
📝 Register Here: https://cancer.miconferences.com/register
💬 Submit Abstract: https://cancer.miconferences.com/abstract-submission
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967
🐦 Follow Updates: @CancerWorldConf

---

#CancerScience2025 #CancerResearch #BreastCancerAwareness #AntitumorMechanisms #MolecularBiology #SPHK1 #MAPKPathway #ERStress #FlavonoidResearch #Safingol #BiomedicalInnovation #UniversityOfBuenosAires #WomenInScience #ScientificDiscovery #OncologyResearch #CancerWorldConf

Transforming Biopsy: Dr. Dmitri Lapotko Unveils Real-Time Cancer Detection Breakthrough

In a remarkable leap toward the future of cancer diagnostics, Dr. Dmitri Lapotko of Scorpido Photonics, Inc, USA, will present his groundbreaking work on “Instant High-Sensitivity Non-Invasive In-Vivo Diagnosis During Biopsy” at the International Conference on Cancer Science and Research, taking place November 17–19, 2025, in Singapore and Online.

Traditional biopsies, though considered the gold standard for cancer diagnosis, often face challenges — invasive procedures, delayed results, and missed microscopic tumors. Dr. Lapotko’s innovation changes that narrative. His Plasmonic Nanobubble (PNB) Diagnostic System enables doctors to detect even microscopic tumors instantly and non-invasively, directly at the tip of a biopsy needle.

---

🔬 Key Highlights of the Presentation:

·         Instant Tumor Detection: The PNB system allows real-time, in-vivo identification of tumors during biopsy without tissue removal.

·         High Sensitivity & Specificity: Delivers precise and rapid diagnostic results, minimizing false negatives.

·         Automation-Ready Technology: Supports AI-driven interpretation, reducing human error and ensuring consistent outcomes.

·         Universal Application: Compatible with all biopsy types — needle, endoscopic, surgical, or robotic — for diverse cancer forms.

·         Empowering Low-Resource Clinics: Designed for accessibility, enabling early cancer detection even in limited-resource healthcare settings.

·         Revolutionizing Patient Care: Turns standard biopsy procedures into an instant diagnostic experience, speeding up treatment decisions.

---

👨‍🔬 About Dr. Dmitri Lapotko:

A distinguished researcher in biophotonics and nanotechnology, Dr. Lapotko holds a Ph.D. in Laser Defense Applications and a Doctor of Science in Bioengineering. His pioneering invention — laser-generated plasmonic nanobubbles — has become a cornerstone for next-generation diagnostic, therapeutic, and surgical innovations in oncology.

---

📅 Event Details:
Conference: International Conference on Cancer Science and Research
Dates: November 17–19, 2025
Venue: Singapore & Online
🌐 Website: https://cancer.miconferences.com/

📩 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 X (Twitter): @CancerWorldConf

🔗 Register Here: https://cancer.miconferences.com/register
🧾 Submit Abstract: https://cancer.miconferences.com/abstract-submission

---

#CancerConference2025 #CancerInnovation #CancerDiagnostics #PlasmonicNanobubbles #OncologyResearch #Biophotonics #Nanotechnology #InVivoDiagnosis #CancerScience #MedicalInnovation #MathewsConferences #SingaporeEvents

ANT2–ATP Synthasome: Powering the Mitochondrial Engine of Breast Cancer Progression

Presenter: Dr. Chia-Jung Li, Kaohsiung Veterans General Hospital, Taiwan

Presentation Type: Poster (In-Person)

Title: Functional Integration of the ATP Synthasome Drives Mitochondrial Efficiency in Breast Carcinoma

---

🔍 Overview

Breast cancer cells possess an extraordinary ability to adapt their energy metabolism, supporting aggressive growth and metastasis. Dr. Chia-Jung Li’s latest research dives into the mitochondrial mechanisms behind this transformation — focusing on the adenine nucleotide translocase 2 (ANT2) protein and its association with the ATP synthasome complex.

The study provides new evidence showing how functional integration between ANT2 and ATP5B boosts mitochondrial efficiency, powering the metastatic potential of breast cancer cells.

---

🌟 Key Research Highlights

·         ANT2 Overexpression in Aggressive Tumors:
Elevated ANT2 levels were linked to poor survival outcomes and increased metastatic activity in breast cancer tissues.

·         Functional Role in Energy Production:
ANT2 knockdown significantly reduced ATP generation, OXPHOS activity, and cell invasion, revealing its central role in tumor metabolism.

·         Therapeutic Discovery – Cymarin:
Through pharmacogenomic screening, cymarin emerged as a potent ANT2 inhibitor, effectively reducing tumor growth and metastasis in preclinical models.

·         Mitochondrial Network Insights:
ANT2 was found to interact with ATP5B, forming a powerful ATP synthasome that enhances energy flux in invasive cancer cells.

·         Clinical Implications:
Targeting ANT2 could be a breakthrough strategy to disrupt mitochondrial energy flow, limiting cancer progression and improving patient outcomes.

---

👨‍🔬 About the Researcher

Dr. Chia-Jung Li is a distinguished mitochondrial biologist and cancer researcher from Taiwan, renowned for his work on mitochondrial dysfunction, cellular metabolism, and aging-related diseases. With over 130 SCI-indexed publications, his research bridges fundamental biochemistry with translational oncology — driving new directions in mitochondria-targeted therapies.

---

🌐 Conference Information

📍 Event: International Conference on Cancer Science and Research
📅 Dates: November 17–19, 2025
🏛️ Venue: Singapore & Online (Hybrid)
🔗 Event Website
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 X (Twitter): @CancerWorldConf
📝 Submit Abstract | Register Now

---

#ANT2 #BreastCancerResearch #MitochondrialFunction #CancerMetabolism #ATP #OXPHOS #CancerTherapy #Mitochondria #Cymarin #Metastasis #OncologyConference #CancerScience2025 #SingaporeConference #CancerResearchInnovation

Redefining Cancer Research with 3D Biomaterial Models

 Keynote Talk by Prof. Subhas C. Kundu, I3Bs – University of Minho, Portugal

Cancer research is entering a new era of innovation — one where 3D biomaterial-based models are transforming how scientists study tumors and test therapies. At the International Conference on Cancer Science and Research, Prof. Subhas C. Kundu will present his groundbreaking work on “3D in vitro cancer models using natural biomaterials for studying the cancer microenvironment and drug screening.”

---

🔬 The Future of Cancer Modeling

Traditional 2D cell cultures often fail to replicate the real behavior of tumors inside the body. Prof. Kundu’s work focuses on three-dimensional biomaterials that recreate the structural and biological complexity of real tumor tissues. These 3D models provide a more physiologically relevant environment for exploring how cancer cells grow, invade, and respond to treatments.

---

🌱 Innovative Use of Natural Biomaterials

In this keynote, Prof. Kundu highlights the power of natural polymers such as:

·         Collagen

·         Hyaluronic acid

·         Alginate

·         Silk

These materials are used to create hydrogels, scaffolds, nanofibers, and bioinks, enabling researchers to build realistic tumor microenvironments in the lab. Among them, silk-based biomaterials stand out for their biocompatibility, strength, and versatility, making them ideal for 3D cancer modeling and tissue engineering.

---

💊 Impact on Drug Screening and Biomedical Research

These 3D systems not only improve the accuracy of drug testing but also help reduce reliance on animal models, supporting ethical and sustainable research practices. By mimicking human tissues more closely, such models can significantly accelerate the discovery of effective cancer therapies.

---

👨‍🔬 About Prof. Subhas C. Kundu

Prof. Kundu is a Research Coordinator at I3Bs – Research Institute on Biomaterials, Biodegradables, and Biomimetics, University of Minho, Portugal.
He previously held the ERA Chair of the European Commission and has authored over 284 research articles, with more than 31,000 citations and an H-index of 85. His research spans biomaterials, tissue engineering, regenerative medicine, and 3D cancer modeling.

---

📅 Event Details

Event: International Conference on Cancer Science and Research
Dates: November 17–19, 2025
Venue: Singapore & Online (Hybrid Event)
🌐 Event Website
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🖋️ Submit Your Abstract
📝 Register Now
🐦 Follow on X: @CancerWorldConf

---

🌟 Key Takeaways

✅ 3D biomaterial systems closely replicate human tumor environments.
✅ Silk-based scaffolds are revolutionizing cancer model design.
✅ Sustainable research methods are reducing animal model dependency.
✅ New insights into drug resistance and cancer progression.

---

#CancerConference2025 #3DBiomaterials #CancerResearch #SilkBiomaterials #DrugScreening #OncologyInnovation #TissueEngineering #RegenerativeMedicine #BiomedicalScience #CancerModeling #ResearchInFocus #CancerAwareness